Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ribavirin · 2 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-72.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ribavirin 200 mg tablets | DRUG | 1 x 200 mg, single-dose fasting |
| COPEGUS™ | DRUG | 1 x 200 mg, single-dose fasting |
| COPEGUS™ 200 mg Tablets | DRUG | 1 x 200 mg, single-dose non-fasting |
Inclusion Criteria: * All subjects selected for this study will be non-smokers, at least 18 years of age, and a female whi is physically unable to become pregnant (postmenopausal for at least 6 months or surgically sterile). Subjects will have a BMI (body mass index) of 30 or less. * Each subject s...
Ribavirin is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials evaluating the drug under fasting and non-fasting conditions. The drug is being developed by Teva Pharmaceutical Industries Limited.
Ribavirin is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker TEVA. The drug is currently in Phase 1 clinical development, with two completed trials in healthy volunteers.
Ribavirin is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy female volunteers aged 18 years and older. The trials were conducted in the United States and evaluated the drug under fasting and non-fasting conditions.
Ribavirin has two completed Phase 1 clinical trials. NCT00835146 evaluated Ribavirin 200 mg tablets under fasting conditions with 28 participants, and NCT00835536 evaluated the same dose under non-fasting conditions with 27 participants. Both trials enrolled healthy female volunteers in the United States.
Ribavirin is an investigational drug currently in Phase 1 clinical development. It has not been approved by the FDA, as it is still being studied in clinical trials. The two completed trials were conducted in healthy volunteers to evaluate the drug's effects under different conditions.